Gelaleti, G. B.
Borin, T. F.
Maschio-Signorini, L. B.
Moschetta, M. G.
Viloria-Petit, A. M.
Zuccari, D. A. P. C.
Total Authors: 7
 Univ Estadual Paulista Julio de Mesquita Filho UN, Programa Posgrad Genet, IBILCE, Sao Jose Do Rio Preto - Brazil
 Fac Med Sao Jose do Rio Preto FAMERP, LIMC, Sao Jose Do Rio Preto - Brazil
 Augusta Univ, Georgia Canc Ctr, Tumor Imaging Angiogenesis Lab, Augusta, GA - USA
 Swedish Univ Agr Sci, Fac Vet Med, Dept Anat Physiol & Biochem, Uppsala - Sweden
 Univ Guelph, Dept Biomed Sci, Ontario Vet Coll, Room 3647, 50 Stone Rd East, Guelph, ON N1G 2W1 - Canada
Total Affiliations: 5
VETERINARY AND COMPARATIVE ONCOLOGY;
Web of Science Citations:
Background: Melatonin has oncostatic actions and IL-25 is active in inflammatory processes that induce apoptosis in tumor cells Aim: The aim of this study was to evaluate melatonin and IL-25 in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumor cells cultured as monolayers and tridimensional structures. Materials and Methods: The cells were treated with melatonin, IL-25 and IL-17B silencing gene and performed cell viability, gene and protein expression of caspase-3 and VEGFA (Vascular endothelial growth factor A) and an apoptosis membrane protein array. Results: Treatment with 1 mM of melatonin reduced cell viability of both tumor cell lines, all treatments alone and combined significantly increased caspase-3 cleaved and proteins involved in the apoptotic pathway and reduced pro-angiogenic VEGFA, confirming the effectiveness of these potential promising treatments. Conclusion: This is the first study evaluating the potential use of these strategies in CF-41 and CMT-U229 cell lines and together encourages subsequent in vitro and in vivo studies for further exploration of clinical applications. (AU)